Skip to main content
Sign In
 

Bradford J. Siegele, MD, JD

PGY II


Education:​

 – 

 – 

 – 

 – 

BA, English & Philosophy; Duke University, Durham, North Carolina (1999)

JD; Harvard Law School, Cambridge, Massachusetts (2005)

Research Fellow; National Institutes of Health, Bethesda, Maryland (2010-2011)

MD; University of Texas Southwestern Medical Center at Dallas Southwestern Medical School, Dallas, Texas (2012)

 ​

Research Interests:​

 – 

 – 

 – 

 – 

Use of gene therapy techniques to target genetically-defined diseases

Whole genome sequencing

Pediatric Pathology

Neuropathology

 

Selected Publications:

 – 

 

 

 

 – 

 

 

 

 – 

 

 

 

Siegele B, Cefalu C, Holm NT, Sun G, Tubbs J, Meschonat C, Odaka Y, DeBenedetti A, Chali GE, Chu QD, Mathis JM, Li BD. elF4E-targeted suicide gene therapy in a minimal residual mouse model for metastatic soft-tissue head and neck squamous cell carcinoma improves disease-free survival. J Surg Res. 2008 Jul; 148(1):83-89.

Patel V, Iglesias-Bartolome R, Siegele B, Marsh CA, Leelahavanichkul K, Molinolo AA, Gutkind JS. Advances in Experimental Medicine and Biology: Human Cell Transformation. In Rihm and Kremer (Ed.), Cellular Systems for Studying Human Oral Squamous Cell Carcinomas (pp. Chapter 3). New York, NY: Springer (2011).

Siegele B, Cefalu C, Holm N, Sun G, Chu QD, Tubbs J, Meschonat C, Odaka Y, Mathis JM, Ghali GE, Li BD. Translation Initiation Factor elF4E-targeted Suicide Gene Therapy Following Cytoreductive Surgery Improves Disease Free Survival In A Mouse Soft Tissue Metastasis Model For Head and Neck Squamous Cell Carcinoma. Poster presented at Ray A. Barlow Scientific Symposium, Shreveport, LA (2008).

 

Contacts:

 Email:

 Pager:

Bradford.Siegele@ucdenver.edu

(303) 266-4041

​​​​​​​​​​​